US45032V1089 - Common Stock
NASDAQ:ISPC (2/3/2023, 7:00:03 PM)-0.07 (-4%)
|GICS Sector||Health Care|
|GICS Industry||Health Care Technology|
|Earnings (Last)||11-08 2022-11-08/bmo||Earnings (Next)||N/A N/A|
|Ins Owners||8.78%||Inst Owners||5.3%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. The company is headquartered in Lexington, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2021-06-17. The firm designed iSpecimen Marketplace platform to transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. The Company’s marketplace platform ingests de-identified healthcare data provided by healthcare supply partners. The iSpecimen Marketplace supports the supply chain management and bioprocurement process for specimens and associated data. The Company’s platform helps with administrating and reporting function for researchers, suppliers, and internal personnel, including user and compliance management. The firm serves to biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions.
450 Bedford St Ste 1010
CEO: Christopher Ianelli
Mr. Langlois Led iSpecimen to 3,000 Percent Revenue Growth During His Tenure as the Company’s Former SVP of Sales and Business Development...
LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that...
LEXINGTON, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that...
Previously Appointed Interim CEO in September 2022...
Sought-After Strategic Advisor Brings Expertise in Mergers and Acquisitions, Restructuring and Governance to iSpecimen...
- Reported Revenue of $2.6 Million, Comprised Of A Record 88% Non-COVID Revenue -...
Here you can normally see the latest stock twits on ISPC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.